Relmada Therapeutics, Inc. announced it will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 PM ET to discuss its financial results for the second quarter ended June 30, 2026. The clinical-stage biotechnology company will also review recent business progress during the session. The announcement provides stakeholders with an opportunity to assess the company's performance and strategic direction in the oncology and central nervous system therapy sectors.

Conference Call Details

The event will be accessible via live webcast and telephone. Investors and interested parties can join the discussion using the following contact details:

Post-Event Access

A replay of the webcast will be made available following the conclusion of the call. Participants can access the archived recording through the Investors section of the Relmada website. This ensures that stakeholders unable to attend the live event can still review the financial results and business updates provided by the management team.

Company Overview

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are currently advancing through mid-stage clinical development. These therapies aim to address significant unmet medical needs within their respective therapeutic areas.

Relmada Therapeutics, Inc. joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution. The inclusion increases visibility among investors and can lead to greater trading volume. Chief Executive Officer Sergio Traversa attributed the milestone to robust 12-month data for NDV-01 in NMIBC and a well-capitalized balance sheet.

The Russell 3000® tracks the 3,000 largest publicly traded U.S. companies and represents roughly 98% of the investable U.S. equity market. The Russell 2000® measures the performance of the small-cap segment, covering 2,000 companies. Membership in both indexes is reconstituted semi-annually, with placement in relevant growth and value style indexes. Both are widely used by institutional investors for index funds and as benchmarks for active strategies.

Relmada is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development.

Relmada's stock trades on the NASDAQ under the ticker symbol RLMD.